Back to results
US 2017/0360834 A1Published application
Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsNick Giannoukakis, Massimo M. Trucco
Life of this patent
Estimating the term…
Abstract
The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
Claims24
1-21. (canceled)
A method for treating an autoimmune condition in a mammal comprising:
- introducing a population of ex vivo manipulated tolerogenic dendritic cells to said mammal, wherein said introducing leads to:
- a. an increased level of suppressive B-cells in said mammal;
- and
- b. decreased level of T cells in said mammal;
- wherein when said population of tolerogenic dendritic cells is introduced in said mammal, an altered ratio of said suppressive B-cells to said T cells results.
2 more elements
Dependencies are inferred from the claim text.